Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

ABSTRACT:

Background

Patients with schizophrenia frequently switch between antipsychotics, underscoring the need to achieve and maintain important treatment outcomes such as health-related quality of life (HRQoL) following the switch. This analysis evaluated HRQoL changes among patients with schizophrenia switched from their current antipsychotic to lurasidone.

Methods

Stable but symptomatic outpatients with schizophrenia were switched from their current antipsychotic to lurasidone in a six-week, open-label trial. HRQoL was assessed using two validated patient-reported measures, the Personal Evaluation of Transitions in Treatment (PETiT) scale and the Short-Form 12 (SF-12). Total and domain scores (psychosocial function and adherence-related attitude) were assessed using the PETiT sca

SUBMITTER: Awad G 

PROVIDER: S-EPMC3936838 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature